C4 Therapeutics

Roche takes ‘leap of faith’ with bet on C4T’s protein degraders

Roche has joined its peers in the degrader-antibody conjugate space, paying C4T more than $1 billion in milestones to partner on two oncology targets.

Nick Paul Taylor Apr 9, 2026 7:00am

C4T halts BRAF degrader work to save cash for cemsidomide

May 7, 2025 7:00am

Less than a year in, BenevolentAI CEO is out—Chutes & Ladders

Oct 18, 2024 8:30am

milkshake ice cream diner dessert open for two cheers

Merck KGaA paying $16M to join C4's protein degrader hunt

Mar 4, 2024 10:18am

Graphic image of someone cutting off a row of stick figures symbolizing employees

C4 lays off 30% of staff in aftermath of halting cancer drug

Jan 10, 2024 5:24am

Graphic image of a pen signing a signature while two strangelooking business people cheer

Merck offers up to $610M for one of C4’s protein degraders

Dec 12, 2023 10:30am